Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 6;6(3):dlae066.
doi: 10.1093/jacamr/dlae066. eCollection 2024 Jun.

Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs

Carolin Bresges  1   2 , Kristina Bresges  3 , Claudette Hewitt  2 , Sunil Sharma  2 , Bethany Davies  1   2
Affiliations

Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs

Carolin Bresges et al. JAC Antimicrob Resist. .

Abstract

Background: Dalbavancin's unique properties have led to an increase in its off-licence use in complex infection and in vulnerable populations including people who inject drugs (PWID), but data remain limited. In this retrospective cohort study, we describe the characteristics, treatment rationale and outcomes for all adult inpatients treated with dalbavancin at a UK tertiary hospital.

Results: Fifty-eight inpatients were treated with dalbavancin between 1 January 2018 and 1 January 2021, 98.3% for off-licence diagnoses. Acute bacterial skin and skin structure infection, infective endocarditis and endovascular infections were each diagnosed in 22.4% of patients. Bone and joint infections were diagnosed in 18.9%, discitis in 12.1% and central line-associated bloodstream infections in 5.2%. Sixty-nine percent of patients were bacteraemic; 52.5% Staphylococcus aureus, 5.0% MRSA. Two mild adverse reactions were attributed to dalbavancin. Treatment was successful in 43 (75.4%) patients, and failed in seven (12.3%). Seven (12.3%) were lost to follow-up.Thirty-five patients (60.3%) were PWID, with low median age (41.0 years) and Charlson Comorbidity scores (0). Self-discharge was taken by 17.1% of PWID, and 20.6% were lost to follow-up. At 90 days, three (8.6%) PWID were deceased.

Conclusions: In this first UK cohort, dalbavancin was used off licence and in persons facing barriers to conventional therapies. Where data is available, it was safe and effective. Dalbavancin appears a potentially valuable tool in improving outcomes for PWID.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient flow diagram.
See this image and copyright information in PMC

References

    1. Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009; 59: S4–16. 10.1016/S0163-4453(09)60003-7 - DOI - PubMed
    1. Doernberg SB, Lodise TP, Thaden JT et al. Gram-positive bacterial infections: research priorities, accomplishments, and future directions of the antibacterial resistance leadership group. Clin Infect Dis 2017; 64: S24–9. 10.1093/cid/ciw828 - DOI - PMC - PubMed
    1. Bouza E, Finch R. Infections caused by Gram-positive bacteria: situation and challenges of treatment. Clin Microbiol Infect 2001; 7: iii. 10.1046/j.1469-0691.2001.00064.x - DOI - PubMed
    1. Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Elsevier, 2015.
    1. Monteagudo-Martínez N, Solís-García Del Pozo J, Ikuta I et al. Systematic review and meta-analysis on the safety of dalbavancin. Expert Opin Drug Saf 2021; 20: 1095–107. 10.1080/14740338.2021.1935864 - DOI - PubMed

LinkOut - more resources